Escaping the ESKAPE Antimicrobial Resistant Cycle with EVQ-218

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) is a growing global health threat, driven by conventional antibiotic use.
• Multidrug- and pan-resistant bacterial pathogens necessitate novel antimicrobial strategies.
• A critical need exists for agents that resist resistance development under selective pressure.

Purpose of the Study:

• To evaluate the novel non-ionic silver-based antimicrobial EVQ-218.
• To assess EVQ-218's activity against World Health Organization-designated ESKAPE pathogens.
• To determine EVQ-218's potential to overcome antimicrobial resistance.

Main Methods:

• Extended serial passage experiments were conducted under sub- and supra-minimum inhibitory concentration (MIC) conditions.
• Comparative resistance selection experiments used tobramycin and ciprofloxacin.
• Susceptibility was evaluated via MIC determination and phenotypic analysis.

Main Results:

• EVQ-218 did not induce measurable increases in MIC or adaptive resistance.
• Tobramycin and ciprofloxacin rapidly elevated MICs, while EVQ-218-exposed isolates remained susceptible.
• No cross-resistance was observed between EVQ-218 and comparator antibiotics.
• Mechanistic studies suggested a multi-site, non-lytic intracellular mechanism distinct from traditional antibiotics.

Conclusions:

• EVQ-218 demonstrates promising resistance-resilient, broad-spectrum antimicrobial activity.
• These findings support EVQ-218 as a potential therapeutic candidate for AMR.
• Further investigation into EVQ-218's role in combating AMR is warranted.